We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Hematology-Oncology

EBMT Crosses One Million Transplants as Allogeneic HCT and CAR-T Reach New Highs in European Cellular Therapy

MedXY Editorial Team•May 30, 2026•Hematology-Oncology
CAR-Tcellular therapyEBMThematopoietic cell transplantation

Section Structure

1. Highlights

2. Background and Clinical Context

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Enhanced Salvage Therapy in Relapsed/Refractory AML: Venetoclax Plus High-Dose Cytarabine and Mitoxantrone Shows Promising Outcomes and Risk Stratification InsightsA multicenter real-world study demonstrates that combining venetoclax with high-dose cytarabine and mitoxantrone significantly improves remission and survival rates in relapsed/refractory AML, with validated risk factors guiding prognosticaAug 24, 2026Extended HLA Haplotypes Linked to Survival After Hematopoietic Cell TransplantationA study of 2,577 haploidentical transplants shows that extended HLA haplotypes, including a class III SNP, significantly influence mortality and relapse, potentially improving donor selection.Jul 27, 2026Fludarabine Dose Intensity, Lymphodepletion Biology, and Product-Specific Outcomes in Large B-Cell Lymphoma CAR-T Therapy: Interpreting the 2026 EBMT Registry AnalysisA large EBMT registry study suggests that escalating fludarabine during lymphodepletion does not improve tisagenlecleucel outcomes in LBCL and may worsen survival, while axicabtagene ciloleucel retains superior efficacy at standard dosing bJun 9, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
The 2024 EBMT Activity Report: Crossing One Million HCTs and 20,000 CAR-T, a Landmark in Cellular Therapy
EBMT’s 2024 report marks over one million reported stem cell transplants and continued rapid CAR-T growth, highlighting shifts in indications, donor use, and access across Europe.
May 30, 2026
Model-Based ATG Dosing Successfully Accelerates CD4+ Reconstitution in CD34+ Selected Allogeneic HCTA Phase 2 study demonstrates that pharmacokinetic model-based ATG dosing significantly enhances CD4+ T-cell reconstitution in patients undergoing CD34+ selected hematopoietic cell transplantation, reaching primary endpoints in 70% of particJan 13, 2026
AZD0120 (GC012F) Dual-Target BCMA/CD19 CAR‑T Shows Promising Early Activity and Favorable Safety in RRMM: Interpreting ASH 2025 Ib DataEarly Ib results from AstraZeneca’s AZD0120 (GC012F), a FasTCAR-derived BCMA/CD19 dual-target CAR‑T, reported 100% ORR in evaluable RRMM patients with low-grade CRS and no ICANS. Findings are encouraging but limited by small numbers and shoDec 9, 2025